Insider · SEC Form 4 filer
Mahkam Zanganeh
Past buys: 1 of 3 beat
Companies
Where they file as an insider
Summit Therapeutics (SMMT) Co-CEO, Director, 10% owner Latest filing Jun 12, 2026
Pulse Biosciences (PLSE) Director Latest filing Feb 3, 2025
Track record
Did their buys beat the typical stock?
Open-market buys10
Quarters checked 6 months later3
Beat the typical stock 1 of 3
Quarters too new to check1
1 of 3 checked quarters beat the typical stock. A past record is data, not a forecast.
Summit Therapeutics (SMMT) Bought Jun 4–12, 2026 · $51.4M · 3.91M shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Summit Therapeutics (SMMT) Bought Oct 21, 2025 · $500K · 26,680 shares Behind typical Dec 31, 2025 $17.49 → Jun 30, 2026 $14.57 · −16.7% (typical stock +4.7%)
Summit Therapeutics (SMMT) Bought Sep 10–11, 2025 · $5.98M · 338,394 shares Behind typical Sep 30, 2025 $20.66 → Mar 31, 2026 $18.96 · −8.2% (typical stock −3.4%)
Summit Therapeutics (SMMT) Bought Mar 26–27, 2024 · $411K · 110,321 shares Not counted Not counted. We have no fund price for this stock on both Mar 31, 2024 and Sep 30, 2024.
Summit Therapeutics (SMMT) Bought Dec 12, 2023 · $10.3K · 5,000 shares Beat typical Dec 31, 2023 $2.61 → Jun 30, 2024 $7.80 · +198.9% (typical stock −1.2%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.